Table of Contents:

1 Report Prologue
2 Market Introduction
2.1 Scope of Study
2.2 Research Objective
2.3 List of Assumptions
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Growing research and development activities and financial support by various private and government organizations for cannabinoid research
4.2.2 Rising prevalence of chronic diseases and other medical conditions
4.2.3 Increasing authorization of marijuana for medical applications
4.3 Restraints
4.3.1 Stringent government policies
4.3.2 Increasing illegal use of marijuana
4.3.3 Side-effects after the intense use of marijuana
4.4 Challenges
4.4.1 Change in government regulations for the use of cannabis for medical applications
5 Market Factor Analysis
5.1 Value Chain Analysis
5.1.1 Overview
5.1.2 R&D
5.1.3 Manufacturing
5.1.4 Distribution & Sales
5.1.5 Post-Sales Monitoring
5.2 Porter's Five Forces Model
5.2.1 Overview
5.2.2 Bargaining Power of Suppliers
5.2.3 Bargaining Power of Buyers
5.2.4 Threat of New Entrants
5.2.5 Threat of Substitutes
5.2.6 Intensity of Rivalry
6 Global Medical Marijuana Market, by Product Type
6.1 Introduction
6.2 Solids
6.3 Dissolvables/Powders
6.4 Oil
6.5 Ointments & Creams
7 Global Medical Marijuana Market, by Application
7.1 Introduction
7.2 Alzheimer's Disease
7.3 Cancer
7.4 Schizophrenia
7.5 Multiple Sclerosis
8 Global Medical Marijuana Market, by Distribution Channel
8.1 Introduction
8.2 Retail & Pharmacy Stores
8.3 Online Platforms
9 Global Medical Marijuana Market, by Region
9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 UK
9.3.1.3 France
9.3.1.4 Italy
9.3.1.5 Spain
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia-Pacific
9.5 Rest of the World
10 Competitive Landscape
11 Company Profile
11.1 Canopy Growth Corporation
11.1.1 Company Overview
11.1.2 Financial Overview
11.1.3 Products/Services Offered
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.1.6 Key Strategy
11.2 Cannabis Sativa Inc.
11.2.1 Company Overview
11.2.2 Financial Overview
11.2.3 Products/Services Offered
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.2.6 Key Strategy
11.3 GW Pharmaceuticals Plc
11.3.1 Company Overview
11.3.2 Financial Overview
11.3.3 Products/Services Offered
11.3.4 Key Developments
11.3.5 SWOT Analysis
11.3.6 Key Strategy
11.4 Emerald Health Therapeutics Inc.
11.4.1 Company Overview
11.4.2 Financial Overview
11.4.3 Products/Services Offered
11.4.4 Key Developments
11.4.5 SWOT Analysis
11.4.6 Key Strategy
11.5 Tilray
11.5.1 Company Overview
11.5.2 Financial Overview
11.5.3 Products/Services Offered
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.5.6 Key Strategy
11.6 Aphria
11.6.1 Company Overview
11.6.2 Financial Overview
11.6.3 Products/Services Offered
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.6.6 Key Strategy
11.7 CanniMed Ltd
11.7.1 Company Overview
11.7.2 Financial Overview
11.7.3 Products/Services Offered
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.7.6 Key Strategy
11.8 Cara Therapeutics
11.8.1 Company Overview
11.8.2 Financial Overview
11.8.3 Pipeline Products
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.8.6 Key Strategy
11.9 Pfizer Inc.
11.9.1 Company Overview
11.9.2 Financial Overview
11.9.3 Clinical Trial Products
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.9.6 Key Strategy
11.1 Medical Marijuana Inc.
11.10.1 Company Overview
11.10.2 Financial Overview
11.10.3 Products/Services Offered
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.10.6 Key Strategy
11.11 GBSciences Inc.
11.11.1 Company Overview
11.11.2 Financial Overview
11.11.3 Pipeline Products
11.11.4 Key Developments
11.11.5 SWOT Analysis
11.11.6 Key Strategy
11.12 MediPharm Labs
11.12.1 Company Overview
11.12.2 Financial Overview
11.12.3 Products/Services Offered
11.12.4 Key Developments
11.12.5 SWOT Analysis
11.12.6 Key Strategy
12 Appendix
12.1 Discussion Blue Print